Mechanistically, the researchers discovered that genetic or pharmacological impairment of ERK5 led to downregulation of NEMO/IKKγ expression, which subsequently resulted in reduced activity of p65/RELA and induced apoptosis in both endometrial cancer cells and xenografts. Here, RELA is linked to endometrial cancer.